Leerink Partners Reiterates Market Perform on Merck (MRK) Following 3Q EPS Beat

KEYTRUDA® (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the companys anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product.

As a company built on a foundation of scientific excellence, Merck is honored to again have been chosen as a recipient of this prestigious award, said Dr. Roger M. Perlmutter, president, Merck Research Laboratories.... More

Merck Announces Third-Quarter 2015 Financial Results

Increased Non-GAAP EPS by 7 Percent to $0.96; GAAP EPS of $0.64 Raised 2015 Full-Year Non-GAAP EPS Target to a Range of $3.55 $3.60 and GAAP EPS Target to a Range of $1.64 $1.74 Worldwide Sales Were $10.1 Billion, a Decrease of 5 Percent; Excluding the Impact of Foreign Exchange, Acquisitions and Divestitures, Worldwide Sales Grew 4 Percent Advanced KEYTRUDA Program FDA Approved sBLA for the Treatment of Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 In KEYNOTE-010 Study KEYTRUDA Showed Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated... More

EMD Millipore Introduces Parteck® SRP 80 Excipient for Sustained-Release Oral Solid Dose Formulations

BILLERICA, Mass., Oct. 26, 2015 /PRNewswire/ -- EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today introduced Parteck® SRP 80, a new functional excipient for oral sustained-release formulations. Parteck® SRP 80 is a polyvinyl alcohol (PVA) based excipient specifically designed for modified-release applications, for optimization of pharmacokinetics and pharmacodynamics as well as the bioavailability of actives. The new excipient is fully synthetic, ensuring batch-to-batch and performance consistency and facilitating quality by design... More

Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1

Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline results from the KEYNOTE-010 study of KEYTRUDA® (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective.

KEYNOTE-010 is a randomized, pivotal Phase 2/3 trial comparing two doses of KEYTRUDA (the FDA-approved 2mg/kg dose and a higher, investigational 10mg/kg dose, each given every 3 weeks), to... More

Merck and the National Sleep Foundation Urge Insomnia Sufferers to Prioritize Sleep and Move Beyond Tired

KENILWORTH, N.J., Oct. 26, 2015 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the National Sleep Foundation today announced the launch of a new educational program that highlights personal stories about sleep for four individuals from across the country. Beyond Tired highlights these individuals' struggles and triumphs, on www.BeyondTired.org, as they strive to refocus on their sleep and how it fits into their busy schedules. By... More